Capricor Therapeutics to Present Exosome Platform Updates at ...

News · Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting · Capricor Therapeutics to ...

Capricor Announces Peer-Reviewed Publication Demonstrating the ...

Capricor's StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-SAN DIEGO, Calif., ...

Exosomes Technology :: Capricor Therapeutics, Inc. (CAPR)

StealthX™ is Capricor's proprietary exosome platform for designer protein surface expression, cargo loading and targeted delivery. StealthX™ technology is at ...

Capricor Announces Publication Highlighting New Advances

Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company's current focus is on developing ...

Exosome research: from platelet dust to pioneering therapeutics | CAS

Though their exosome platform is still in the preclinical stages, they have seen promising data in several indications and partnered with other ...

Capricor Therapeutics Signs Exclusive Worldwide License ...

Capricor is also developing our exosomes platform technology as a next- generation therapeutic platform. Our current focus is on the ...

Capricor publishes new advances for its engineered exosome platform

StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Therapeutics a ...

Capricor Therapeutics Signs Exclusive Worldwide ... - SEC.gov

Gould and his colleagues at JHU, we believe that exosomes can provide a new approach in drug development. Capricor plans to announce further ...

We were pleased to present... - Capricor Therapeutics, Inc. - Facebook

We were pleased to present new preclinical data highlighting the therapeutic potential of our StealthX™ exosome platform at the 2024 American Association...

Capricor Therapeutics to Host a Key Opinion Leader Call On Why ...

Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Additionally, he will discuss ...

Capricor Therapeutics - Crunchbase Company Profile & Funding

A proprietary exosome platform technology for designer protein surface expression, cargo loading, and targeted delivery, aimed at developing precision ...

Capricor Therapeutics Advances with Strategic Expansions

Capricor Therapeutics, Inc., a biotechnology company, specializes in developing innovative cell and exosome-based therapies for rare diseases, ...

Capricor Therapeutics to Present Third Quarter 2022 Financial ...

Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company's current focus is on developing ...

Capricor Announces Publication Highlighting New Advances for its ...

“We are encouraged with the results of this study as it underscores the therapeutic utility of Capricor's engineered exosome program and ...

Six exosome therapy companies driving development in the field

Capricor Therapeutics is focused on advancing transformative cell and exosome-based therapeutics, with a mission of redefining the treatment ...

Capricor Therapeutics: CAP-1002 HOPE-3 Program Update

PPMD and Capricor Therapeutics held a community webinar on October 25, 2023 to provide an overview of the latest regulatory developments for ...

Capricor Therapeutics Announces Publication Demonstrating ...

We have dedicated the last few years at Capricor to understanding the molecular composition of our exosomes products in order to identify ...

Capricor Therapeutics - X

... exosome-based therapeutics for treatment and prevention of serious diseases ... provide the latest updates on our deramiocel program for the treatment of DMD.

Capricor Therapeutics Inc. (NASDAQ: CAPR) Stock Information

The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and ...

Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD ...

Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy · Phase III trial planned. The NS Pharma-Capricor partnership will ...